Latest News for China Education Group Stock (OTC:CEGHF)

China Education Group Holdings Ltd is a leading ultra-large-scale private education group in China with 30 years of experience in higher education operations. CEG's schools offer both higher vocational education and secondary vocational education. The school network spans domestic China and overseas. CEG also offers continuing education to full-time working adults. The group's total enrolled full-time students in China expanded more than 3 times over the last six years to about 248,000 as of August 2023. The rapid growth is primarily attributable to school acquisitions. CEG currently operates 14 schools, up from only 3 in 2017.

CHINA ED GROUP HLDGS LTD by CHINA ED GROUP HLDGS LTD.

China Education Group Holdings Ltd

DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), the local commerce platform, and Walgreens (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), a trusted, neighborhood health destination serving nearly 10 million customers each day, today announced a new collaboration to offer SNAP/EBT payment at nearly 7,800 <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.doordash.com%2Fbusiness%2Fwalgreens-434024%2F&amp;esheet=53951735&amp;newsitemid=20240424416259&amp;lan=en-US&amp;anchor=Walgreens+stores&amp;index=1&amp;md5=7d828216c4546f32c5f0b2223e83f84f">Walgreens stores</a> across the country. DoorDash is the first platform that enables SNAP customers to make purchases directly from Walgreens using their SNAP/EBT cards. In addition, DoorDash is the first third-party delivery service provider (DSP) to offer SNAP/EBT as a payment option at a major drugstore nationwide.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240424416259/en/">https://www.businesswire.com/news/home/20240424416259/en/</a>
&nbsp;
With the addition of Walgreens, DoorDash more than doubles the number of stores available for on-demand delivery with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.doordash.com%2Fp%2Fsnap-ebt&amp;esheet=53951735&amp;newsitemid=20240424416259&amp;lan=en-US&amp;anchor=SNAP%2FEBT&amp;index=2&amp;md5=f41d03622e529faf6a95afd60c5514c9">SNAP/EBT</a> payments on DoorDash. We continue to broaden food access by offering SNAP/EBT access to more than 14 million people who are living in food deserts, and over 40 million people living in communities where over 1 in 10 households receive SNAP/EBT benefits.
"Since launching support for SNAP/EBT payments in 2023, over 1.1 million consumers have added their SNAP/EBT cards to DoorDash," said Fuad Hannon, VP of New Verticals. "This first-of-its-kind partnership with Walgreens offers convenient and critical access to food and pantry essentials for families and individuals across the country. We're proud to remove as many barriers as possible when it comes to connecting people with food, wherever they live and however they choose to shop."
As prices continue to rise on groceries and household essentials, consumers can order SNAP-eligible products using their SNAP benefits from their local Walgreens through DoorDash. Walgreens will offer more than 4,000 SNAP-eligible products for delivery within an hour on DoorDash.1 Whether it's stocking up on breakfast essentials including milk, oatmeal, or juice, or pantry staples such as nuts, bars, or snacks, consumers can shop the Walgreens marketplace directly on the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fapps.apple.com%2Fus%2Fapp%2Fdoordash-food-delivery%2Fid719972451&amp;esheet=53951735&amp;newsitemid=20240424416259&amp;lan=en-US&amp;anchor=DoorDash+app&amp;index=3&amp;md5=472113558ce6036972ad87c96c3db294">DoorDash app</a> to fulfill their grocery needs quickly and affordably.
"This collaboration with DoorDash means our shoppers can now get essential grocery items when they want, regardless of payment method and other barriers like work schedules and transportation," said Balachandra Visalatha, SVP, Chief Product Officer at Walgreens. "Walgreens is a go to destination for daily needs for our shoppers and we continue to find solutions that make their shopping experience simpler so they can get access to healthier food options."
DoorDash is one of the largest online marketplaces to offer SNAP/EBT recipients' access to grocery delivery across the country. Now, nearly all DoorDash's monthly active users have access to a SNAP store across all 50 states and Washington D.C. To further our commitment to increase access to food, DoorDash is excited to offer SNAP/EBT consumers, who are currently not DashPass subscribers, $0 delivery fee on up to 3 orders paid with SNAP at Walgreens.&#x2A; DashPass members can access thousands of restaurants, grocery, and convenience stores at affordable prices, with $0 delivery fees and reduced service fees on eligible orders. DashPass members save $5 per eligible order on average.
Currently, Walgreens stores accept SNAP/EBT in-person at most locations. This collaboration with DoorDash allows shoppers across the nation to use SNAP/EBT at any Walgreens, regardless of where they live.

News

DASH

DoorDash And Walgreens Launch Unprecedented Access For SNAP Customers; DashPass Members Save $5 Per Eligible Order On Average

Capitol Federal Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFN#NASDAQ">CFFN</a>) reported quarterly earnings of $0.11 per share which met the analyst consensus estimate. This is unchanged from the same period last year.

Earnings

CFFN

Capitol Federal Finl Q2 EPS $0.11, Inline

Mini Tractor and Mini 125 Go&nbsp;Kart to be Eligible for Sale in a Major U.S. Retailer in its 1,300 Stores Across 13 States

MAMO

Massimo Group Expands Partnership With Global Omnichannel Retailer For Youth Series Vehicles

WIIM

TPET

Trio Petroleum shares are trading higher after the company announced it commenced oil sales from its California assets.

Biotech

General

HSCS

HeartSciences Says European Patent Office Application EP3834729 Has Been Granted

2024 Fiscal Year Guidance
The Company currently expects to achieve the following financial performance for the upcoming year ending December 31, 2024:
<ul>
<li>Net sales to be between $1.36 billion and $1.56 billion.</li>
<li>GMV to be between $1.74 billion and $1.90 billion.</li>
<li>Gross profit to be between $154.6 million and $171.7 million.</li>
<li>Net loss to be between $42.8 million and $51.7 million.</li>
<li>Adjusted EBITDA to be between $(9.6) million and $0.2 million.</li>
</ul>
The Company anticipates filing its annual report on Form 20-F for the fiscal year ended December 31, 2023, on April 24, 2024.

Guidance

NEGG

Newegg Sees FY24 Revenue $1.36B-$1.56B

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Hold and raises the price target from $145 to $150.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $150

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant
This transplant builds on two successful UHeart transplants completed in 2022 and 2023

UTHR

United Therapeutics Announces Xenothymokidney Transplant

BranchOut Food shares are trading higher after the company announced it has expanded its existing relationship with the nation's largest retailer, which brings the total annualized value of commitments from the retailer to over $8 million.

2023 Fiscal Year Financial Highlights
<ul>
<li>Net sales decreased to $1.50 billion, compared to net sales of $1.72 billion in fiscal year 2022.</li>
<li>GMV decreased to $1.81 billion, compared to GMV of $2.20 billion in fiscal year 2022.</li>
<li>Gross profit decreased to $167.6 million, compared to gross profit of $216.7 million in fiscal year 2022.</li>
<li>Net loss increased to $59.0 million, compared to net loss of $57.4 million in fiscal year 2022.</li>
<li>Adjusted EBITDA decreased to ($21.3) million, compared to Adjusted EBITDA of $0.6 million in fiscal year 2022.</li>
</ul>
2023 Fiscal Year Operational Metrics
<ul>
<li>Average order value was $379 for the year ended December 31, 2023, compared to $411 for the prior year.</li>
<li>Active customers, defined as unique customer IDs with at least one item purchased on Newegg platforms in the past 12 months, totaled approximately 2.5 million as of December 31, 2023, a decrease from 2.7 million the prior year.</li>
<li>Repeat purchase rate, the percentage of active customers who made at least two purchases on Newegg platforms during the past 12 months, was 29.2% as of December 31, 2023, compared to 31.3% for the prior year.</li>
</ul>

Newegg FY23 Revenue $1.5B Vs $1.72B YoY; Average Order Value Was $379 In FY23 Vs $411 In FY22

Beleaguered EV maker Fisker Inc. said on Tuesday that it expects to seek <a href="https://www.benzinga.com/markets/equities/24/03/37766138/teslas-india-entry-hurdle-lifts-fisker-hurtling-toward-bankruptcy-rivian-gets-wall-streets-love-">protection under bankruptcy laws </a>within 30 days if unable to receive waivers from its debt holders or raise enough capital to settle its dues. 
What Happened: The company is seeking to restructure its current debts and discussing financing alternatives, it said in a regulatory filing, while adding that there is no assurance it will be able to do either.
Additionally, the company will reduce its workforce and streamline its operations in a bid to cut costs, it added. &nbsp;
Fisker in February warned that it may not have enough funds to operate over the year. The company's shares were delisted from the New York Stock Exchange in March owing to low share prices and potential investment talks with a major automaker collapsed, leaving Fisker&#8217;s financial future uncertain.
Why It Matters: Fisker&#8217;s cash balance dwindled from $736.5 million at the end of 2022 to $325.5 million by December 2023. The company&nbsp;<a href="https://www.benzinga.com/news/earnings/24/02/37407754/whats-going-on-with-fisker-stock-after-hours" target="_blank" rel="noreferrer noopener">reported a net loss</a>&nbsp;of $463.6 million and revenue of $200.1 million for the fourth quarter. Despite producing around 10,200 Ocean SUVs in 2023, Fisker only managed to deliver 4,929 vehicles during the year.&nbsp;
To address inventory and financing issues, Fisker initiated a six-week production pause in March. The company also announced price cuts of as much as $24,000 on its Ocean SUV last month to drive sales.
Fisker is not alone in its troubles. EV maker Canoo Inc. <a href="https://www.benzinga.com/news/earnings/24/04/38036342/ev-maker-canoos-stock-falls-on-mixed-q4-results">warned about its ability to continue as a going concern</a> without additional funding earlier this month. Lordstown Motors <a href="https://www.benzinga.com/news/23/06/33017879/lordstown-motors-files-for-bankruptcy-protection">filed for bankruptcy protection </a>last year. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/mobility" rel="noreferrer noopener">following this link</a>.
Read More:&nbsp;<a href="https://www.benzinga.com/news/24/04/38397845/tesla-will-solve-autonomy-even-if-i-got-kidnapped-by-aliens-tomorrow-says-elon-musk-as-he-reveals-ta">Tesla Will Solve Autonomy ‘Even If I Got Kidnapped By Aliens Tomorrow,' Says Elon Musk As He Reveals Talks With ‘Major Automaker' For FSD Licensing</a>
Image Via Shutterstock

Tech

Fisker To File For Bankruptcy Protection In 30 Days If Unable To Settle Debts Or Raise Capital

Canaccord Genuity analyst Maria Ripps maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $330 to $370.

SPOT

Canaccord Genuity Maintains Buy on Spotify Technology, Raises Price Target to $370

CAPR

Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting

Truist Securities analyst Michael Swartz maintains Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) with a Hold and lowers the price target from $96 to $92.

Truist Securities Maintains Hold on Polaris, Lowers Price Target to $92

Canadian Pacific Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) reported quarterly earnings of $0.93 per share which missed the analyst consensus estimate of $0.94 by 1.06 percent. The company reported quarterly sales of $3.52 billion which missed the analyst consensus estimate of $3.54 billion by 0.52 percent. This is a 110.02 percent increase over sales of $1.68 billion the same period last year.

Earnings Misses

Canadian Pacific Railway Q1 2024 Adj EPS CAD$0.93 Misses CAD$0.94 Estimate, Sales CAD$3.52B Miss CAD$3.54B Estimate

SNOW

Snowflake Launches Arctic Enterprise-Grade Large Language Model

Truist Securities analyst Michael Ciarmoli maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Buy and lowers the price target from $90 to $88.

Truist Securities Maintains Buy on Hexcel, Lowers Price Target to $88

Analysts' ratings for Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.86, a high estimate of $37.00, and a low estimate of $23.00. This upward trend is apparent, with the current average reflecting a 3.88% increase from the previous average price target of $30.67.
<img src="https://www.benzinga.com/files/images/story/2024/1713963672_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Guess among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$29.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$32.50</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.50</td>
<td>$32.50</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Guess. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Guess compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Guess's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GES/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Guess analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Guess: A Closer Look</h2>
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
<h3>Guess: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Guess's remarkable performance in 3 months is evident. As of 31 January, 2024, the company achieved an impressive revenue growth rate of 8.96%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Guess's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Guess's ROE excels beyond industry benchmarks, reaching 19.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Guess's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.7, Guess adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Guess

In the latest quarter, 7 analysts provided ratings for East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated East West Bancorp and provided 12-month price targets. The average target is $91.71, accompanied by a high estimate of $106.00 and a low estimate of $88.00. Surpassing the previous average price target of $83.00, the current average has increased by 10.49%.
<img src="https://www.benzinga.com/files/images/story/2024/1713963663_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive East West Bancorp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Elan Zanger</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Dave Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$106.00</td>
<td>-</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$76.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to East West Bancorp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of East West Bancorp compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of East West Bancorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of East West Bancorp's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EWBC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on East West Bancorp analyst ratings.</a>
<h2>Get to Know East West Bancorp Better</h2>
East West Bancorp Inc is the holding company for East West Bank, a full-service commercial bank with cross-border operations concentrated in the United States and China. East-West Bank is one of a few U.S. based banks with a full banking license in China. The bank's cost strategy has increasingly focused on expanding its deposit base away from time deposits to commercial deposits. The bank has also taken part in entertainment partnerships between participants in China and Hollywood. Most of these efforts include financing the production and distribution of film and television projects. The bank leverages its cultural and regulatory knowledge in the U.S. and China to assist its customers in entering new markets. Most of its earning assets are in loans held for investment.
<h3>East West Bancorp: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: East West Bancorp's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -2.82%. This indicates a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 37.14%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): East West Bancorp's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): East West Bancorp's ROA stands out, surpassing industry averages. With an impressive ROA of 0.35%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.68, East West Bancorp faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

Expert Outlook: East West Bancorp Through The Eyes Of 7 Analysts

Renovaro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo. &nbsp;
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given," according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.&nbsp;
RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength' providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection," added Dr. Henk Viëtor (MD/PHD).
Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq' for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay&nbsp;in partnership with Oxford Nanopore&nbsp;that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.
"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."